Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes by unknown
Bouchi et al. Cardiovasc Diabetol  (2016) 15:64 
DOI 10.1186/s12933-016-0384-7
ORIGINAL INVESTIGATION
Clinical relevance of dual-energy 
X-ray absorptiometry (DXA) as a 
simultaneous evaluation of fatty liver disease 
and atherosclerosis in patients with type 2 
diabetes
Ryotaro Bouchi1*, Yujiro Nakano1, Norihiko Ohara1, Takato Takeuchi1, Masanori Murakami1, Masahiro Asakawa1, 
Yuriko Sasahara1, Mitsuyuki Numasawa1, Isao Minami1, Hajime Izumiyama1,2, Koshi Hashimoto1,3, 
Takanobu Yoshimoto1 and Yoshihiro Ogawa1,4
Abstract 
Background: Whole body dual-energy X-ray absorptiometry (DXA) can simultaneously measure both regional fat 
and non-fat mass. Android-to-gynoid (A/G) ratio measured by DXA has been reported to be associated with cardio-
vascular risks and visceral adiposity; however, little is known regarding its relationship with fatty liver disease and 
atherosclerosis among patients with diabetes. This study was designed to investigate the association of android and 
gynoid fat mass measured by DXA with fatty liver disease and atherosclerosis in patients with type 2 diabetes.
Methods: This is a cross-sectional study of 259 patients with type 2 diabetes (mean age 64 ± 13 years; 40.2 % 
female). Android and gynoid fat mass (kg) were measured by DXA. Skeletal muscle index (SMI) was calculated as 
appendicular non-fat mass (kg) divided by height (m2). Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), 
and liver attenuation index (LAI) were assessed by abdominal computed tomography. Intima media thickness (IMT, 
mm) in common carotid arteries was determined by carotid ultrasonography.
Results: A/G ratio was significantly correlated with VFA (r = 0.72, p < 0.001), SFA (r = 0.32, p < 0.001) and LAI 
(r = −0.26, p < 0.001). A/G ratio (standardized β −0.223, p = 0.002) as well as VFA (standardized β −0.226, p = 0.001) 
were significantly associated with LAI in the univariate model. A/G ratio remained to be significantly associated with 
LAI (standardized β −0.224, p = 0.005) after adjusting for covariates including body mass index and transaminases. 
Among patients with low SMI (SMI < 7.0 in male and < 5.4 in female), A/G ratio was significantly associated with 
carotid IMT in the multivariate model (standardized β 0.408, p = 0.014).
Conclusions: DXA can be used to simultaneously estimate the risks for both fatty liver disease and atherosclerosis in 
patients with type 2 diabetes.
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Background
Obesity, especially visceral obesity, has been reported 
to be associated with insulin resistance, dyslipidemia, 
and hypertension, thus increasing the risk for cardio-
vascular disease (CVD) [1–4]. Abdominal visceral fat 
has been strongly associated with cardiovascular risks 
[5, 6]. However, direct measure of visceral fat is limited 
due to high cost of imaging procedures such as com-
puted tomography (CT) or magnetic resonance imaging 
(MRI). Dual-energy X-ray absorptiometry (DXA) is the 
one that can estimate the risk for visceral fat accumula-
tion with low-cost, relatively quick procedure, and less 
exposure to ionizing radiation, compared with CT [7, 
8]. The clinical utility of DXA is the following; (1) it can 
measure regional fat mass, compared with anthropologi-
cal methods such as body mass index (BMI), (2) fat-free 
mass, mainly reflecting skeletal muscle mass, can be esti-
mated by DXA both in Caucasians and Asians [9–11], 
leading to the simultaneous evaluation of fat and muscle 
mass. It is reported that regional fat mass such as android 
is associated with cardio-metabolic risks [12, 13] and 
android-to-gynoid ratio (A/G ratio), reflecting visceral fat 
accumulation, is associated with insulin resistance [14].
Non-alcoholic fatty liver disease (NAFLD) has recently 
been thought to be a hepatic manifestation of meta-
bolic syndrome [15, 16] and patients with NAFLD are 
at increased risk for diabetes and CVD [17, 18]. Thus, 
it is important to measure hepatic fat accumulation for 
evaluating cardio-metabolic risks as well as the risk for 
the progression of liver disease; however, the use of CT 
or MRI is limited due to the high cost and low feasibility. 
It is also uncertain whether regional fat mass and indices 
such as A/G ratio measured by DXA could estimate the 
risk for NAFLD.
CVD is a leading cause of death worldwide. In order to 
estimate the risk for CVD events, carotid intima media 
thickness (CIMT) is thought to be a good marker and is 
associated with incident CVD [19]. Regarding the associ-
ation of visceral adiposity and CVD, it has been reported 
that visceral fat mass is significantly associated with inci-
dent CVD [20]. Conversely, several previous studies have 
shown that peripheral subcutaneous fat may represent 
a “metabolic sink” for the storage of excess energy and 
may act against metabolic alterations and atherosclero-
sis [21, 22]. We recently reported that visceral adipos-
ity is associated with arterial stiffness regardless of BMI 
[23] and visceral-to-subcutaneous fat ratio by abdominal 
CT is closely associated with CIMT among patients with 
type 2 diabetes [24]. Others also reported that subcuta-
neous abdominal fat is inversely associated with carotid 
atherosclerosis in patients with type 2 diabetes [25]. In 
addition to visceral and subcutaneous adiposities, skel-
etal muscle mass is another important determinant 
of cardio-metabolic alterations and atherosclerosis. 
Reduced skeletal muscle mass and muscle power (sar-
copenia) and increased visceral adiposity are synergisti-
cally associated with atherosclerosis as well as diabetes 
and fatty liver disease [26–28]. These studies suggest the 
importance of evaluating both visceral and subcutane-
ous adiposities and muscle mass for the assessment of 
atherosclerosis.
Considering the potential of DXA in that regional fat 
and muscle mass can be simultaneously determined, this 
study was designed to investigate whether DXA could be 
valuable to concurrently estimate risks for both NAFLD 
and atherosclerosis in patients with type 2 diabetes.
Methods
Subjects
Patients with type 2 diabetes with 20  years of age or 
older, who were diagnosed as diabetes according to the 
criteria of the Japan Diabetes Society [29], regularly vis-
ited to Tokyo Medical and Dental University Hospital for 
the purpose of glycemic control, and had undergone the 
whole body DXA for the evaluation of A/G ratio between 
July 1, 2012 and December 31, 2015 participated in this 
study. Patients with alcohol consumption ≥20  g/day in 
female and 30  g/day in male, severe renal impairment 
[estimated glomerular filtration rate (eGFR) <15  ml/
min/1.73  m2 or undergoing renal replacement therapy], 
pregnant women, those with infectious or malignant dis-
eases, and those without measurement of both visceral fat 
area (VFA), subcutaneous fat area (SFA) and hepatic fat 
accumulation [liver-spleen-attenuation index (LAI)] by 
abdominal CT were excluded. We also excluded patients 
who had received hepatotoxic drugs including gluco-
corticoids, tamoxifen, amiodarone, sodium valproate, 
and methotrexate, and those with other causes of liver 
diseases such as viral hepatitis (hepatitis B virus/hepati-
tis C virus) and autoimmune liver diseases. In addition, 
we excluded patients who had a history of gastrectomy, 
bariatric or intestinal surgery, malabsorption, those with 
severe heart failure, those with overt endocrine abnor-
malities such as hyperthyroidism, those with eating dis-
order, and those treated with estrogens or anti-psychotics 
were also excluded, because these diseases or drugs could 
affect body fat and muscle composition including hepatic 
fat accumulation. This study complies with the principles 
laid by Declaration of Helsinki and has been approved by 
the ethical committee of Tokyo Medical and Dental Uni-
versity (No. M2015-508).
Clinical and biochemical analysis
Standardized questionnaires were used to obtain infor-
mation on smoking, medication and past history. Smok-
ing history was classified as either current smoker or 
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non-smoker. CVD was defined as the presence of a pre-
vious stroke, myocardial infarction, coronary revascu-
larization procedure. Information regarding diabetic 
retinopathy was obtained using medical records and 
the prevalence of proliferative diabetic retinopathy was 
determined. HbA1c was measured by the latex agglutina-
tion method. HbA1c levels were expressed in accordance 
with the National Glycohemoglobin Standardization 
Programs recommended by the Japanese Diabetes Soci-
ety [29]. Systolic and diastolic blood pressures (SBP and 
DBP) were measured in the sitting position after at least 
5 min rest, using an electronic sphyngomanometer (ES-
H55, Terumo Inc., Tokyo, Japan). Urinary albumin and 
creatinine excretion were measured by the turbidimetric 
immunoassay and enzymatic method, respectively, in a 
spot urine collection. GFR was estimated using the fol-
lowing equation for the Japanese, as proposed by the Jap-
anese Society of Nephrology [30]; GFR = 194 X SCr−1.094 
X age−0.287 [(if female) X 0.739], where SCr stands for 
serum creatinine in mg/dl, measured by an enzymatic 
method. Coefficient of variation of R–R intervals (CV-
RR) was used for the assessment of diabetic neuropathy. 
BMI was calculated as weight divided by the square of 
height (kg/m2).
Body composition measured by DXA
Regional fat mass was measured by the whole body DXA 
(Lunar iDXA, GE Healthcare, Madison, WI). The scans 
were done by certified radiological technologists who 
were blinded to the patient characteristics and labora-
tory data. The imaging machine was calibrated everyday 
according to the manufacturer’s recommendations. Total 
and regional scans were taken and two regions (android 
and gynoid) were considered of interest in this study. The 
regions of interest (ROI) for regional body composition 
were defined as previously reported [31]. Briefly, ROI of 
android was defined as the region from pelvis cut (lower 
boundary) to above the pelvis cut by 20 % of the distance 
from pelvis cut line to neck cut line (upper boundary). 
ROI of gynoid was defined as the region among the 2× 
Android height, beginning at a distance of 1.5× Android 
height below pelvis cut (Fig. 1). A/G ratio was the ratio 
of android (kg) divided by gynoid (kg). Skeletal muscle 
index (SMI) was calculated as the following: SMI = (fat-
free mass in upper and lower extremities, kg) divided by 
height (m2). According to the criteria of sarcopenia in 
Asia [13], Patients were divided into the following two 
groups; patients with high SMI (SMI ≥ 7.0 in male and 
≥5.4 in female) and those with low SMI (SMI  <  7.0 in 
male and <5.4 in female).
Quantification of abdominal adiposity, hepatic fat 
accumulation, and atherosclerosis
VFA and SFA were measured at the level of umbilicus by 
abdominal CT examination (Aquilion PRIME, Toshiba 
Medical Systems, Tochigi, Japan). As well as the whole 
body DXA, the scans were done by certified radiologi-
cal technologists who were blinded to the patient char-
acteristics and laboratory data and the imaging machine 
was calibrated everyday according to the manufacturer’s 
recommendations. Hepatic fat accumulation was deter-
mined by LAI in the CT examination, as described previ-
ously [32]. Briefly, hepatic and splenic attenuation values 
were measured on non-contrast CT scans by using eight 
circular ROI cursors with a diameter of 1.5 cm in the liver 
and 3 in the spleen. In the liver, four ROIs were located in 
each of the right anterior, right posterior, left medial, and 
left lateral segments. In this study, the LAI was evaluated 
for its efficacy as a marker for steatosis in the liver. Calcu-
lation of LAI was as follows: Average attenuation value of 
liver (eight points) divided by average attenuation value 
of spleen (three points). Atherosclerosis was assessed 
by CIMT using an echotomographic system (Aplio XG 
SSA790A, Toshiba Medical Systems, Tochigi, Japan) with 
a 7.5-MHz linear transducer, as reported previously [24].
Statistical analysis
Statistical analysis was performed using programs avail-
able in the SPSS version 21.0 statistical package (IBM 
Corp. Released 2012. IBM SPSS Statistics for Windows, 
Version 21.0. Armonk, NY: IBM Corp.). Data are pre-
sented as mean ± standard deviation (SD), median with 
interquartile range (IQR), or percent as appropriate 
according to data distribution. Normality was tested by 
the Kolmogorov–Smirnov test. Differences between male 
and female patients were tested with a t test or Mann–
Whitney U test (continuous variables) or Chi square test 
(categorical variables). Pearson product-moment corre-
lation analysis was used to investigate the correlation of 
A/G ratio with measures for adiposity and LAI. Linear 
Fig. 1 Regional body composition measurement by dual-energy 
X-ray absorptiometry (DXA). Regions of interest (ROI) in android and 
gynoid are shown in the right panel
Page 4 of 9Bouchi et al. Cardiovasc Diabetol  (2016) 15:64 
regression analyses with a stepwise procedure were used 
to assess the cross-sectional association of A/G ratio with 
LAI and CIMT. We determined the linear relationship 
and multicollinearity for regression assumptions. We 
removed one variable if a strong correlation (coefficient 
of correlation >0.8) was observed between the two inde-
pendent variables. In order to check the multicollinearity, 
we evaluated variance infiltration factors. If multicollin-
earity was found in the data, one variable was removed 
from the multivariate regression analysis. The follow-
ing covariates were incorporated into the multivari-
ate analysis; duration of diabetes, smoking status, BMI, 
SBP, triglycerides (TGs), high-density lipoprotein (HDL) 
cholesterol, alanine aminotransferase (ALT), HbA1c, 
eGFR, and the use of insulin. Age and gender were forced 
into the model. The interaction between A/G ratio and 
SMI was also investigated where CIMT was used for a 
dependent variable. Differences were considered to be 
statistically significant at p value less than 0.05.
Results
Clinical characteristics
A total of 259 Japanese patients with type 2 diabetes 
(mean age 64 ±  12 years; 40.2 % female) were enrolled 
in this study. Table 1 shows the clinical characteristics by 
gender. Male patients exhibited significantly higher TGs, 
uric acid, ALT and glutamyl transpeptidase (γ-GTP), 
and lower HDL cholesterol levels than female patients. 
There were no significant differences in age, BMI, gly-
cemic control, blood pressure, low-density lipoprotein 
(LDL) cholesterol, aspartate transaminase (AST), LAI, 
and prevalence of diabetic microvascular complica-
tions including retinopathy and nephropathy. SMI and 
VFA were significantly higher and android tended to be 
higher in male than those in female; by contrast, per-
centage of body fat, gynoid and SFA were significantly 
lower in male than those in female. Eventually, male 
patients had significantly higher A/G ratio and V/S ratio 
than female.
Correlation of A/G ratio with markers for body composition
As shown in Table  1, there were definite differences in 
body fat composition between male and female; thus, we 
investigated the correlation between A/G ratio and VFA 
by gender. Figure  2 shows the correlation between A/G 
ratio and VFA among the patients. A/G ratio was sig-
nificantly and strongly correlated with VFA both in male 
(r  =  0.72, p  <  0.001) and female (r  =  0.70, p  <  0.001). 
Compared with the relationship between A/G ratio and 
VFA, the correlations of A/G ratio with other markers for 
body composition were weak (r = 0.32 and p < 0.001 for 
SFA, r = 0.26 and p = 0.001 for percentage of body fat, 
r = 0.52 and p < 0.001 for BMI).
Association of A/G ratio and VFA with hepatic fat 
accumulation
Figure 3 shows the correlation of A/G ratio (Fig. 3a) and 
VFA (Fig.  3b) with LAI among the patients. A/G ratio 
was modestly correlated with LAI (r = −0.26, p < 0.001) 
and its relationship was almost identical to the relation-
ship between VFA and LAI (r = −0.37, p < 0.001). In the 
univariate linear regression model as shown in Table  2, 
A/G ratio was significantly associated with LAI (stand-
ardized β −0.223, p = 0.002). A/G ratio remained to be 
significantly associated with LAI after adjustment for 
Table 1 Clinical characteristics of patients with type 2 dia-
betes by gender
ACR albumin-to-creatinine ratio, A/G android-to-gynoid, ALT alanine 
aminotransferase, AST Aspartate aminotransferase, eGFR estimated glomerular 
filtration rate, γ-GTP γ-glutamyl transpeptidase, HDL high-density lipoprotein, 
LAI liver attenuation index, LDL low-density lipoprotein, V/S visceral-to-
subcutaneous fat
Male (N = 155) Female (N = 104) p value
Age (years) 63 ± 12 64 ± 13 0.570
Body mass index  
(kg/m2)
25.1 ± 4.1 24.2 ± 4.4 0.128
HbA1c (%) 7.2 ± 1.4 7.1 ± 1.5 0.600
Duration of diabetes 
(years)
7 (2–16) 7 (3–10) 0.958




Insulin (%) 30 36 0.358
Systolic blood pressure 
(mmHg)
129 ± 14 124 ± 15 0.442
Diastolic blood pressure 
(mmHg)
77 ± 13 71 ± 15 0.338
Uninary ACR (mg/g) 33 (20–148) 26 (13–54) 0.209
eGFR (ml/min/1.73 m2) 75 ± 12 69 ± 13 <0.001
TG (mmol/l) 1.48 (1.30–1.71) 1.22 (1.02–1.47) 0.045
HDL cholesterol 
 (mmol/l)
1.45 ± 0.38 1.60 ± 0.47 0.002
LDL cholesterol 
 (mmol/l)
2.64 (2.19–3.17) 2.69 (2.17–3.72) 0.308
Uric acid (μmol/l) 333 ± 77 286 ± 65 <0.001
AST (U/l) 25 (20–34) 22 (18–28) 0.402
ALT (U/l) 26 (16–45) 20 (15–33) 0.047
γ-GTP (U/l) 42 (31–53) 30 (20–40) <0.001
Body fat (%) 30.8 ± 6.8 38.7 ± 7.2 <0.001
Skeletal muscle index 7.2 ± 1.1 5.8 ± 1.0 <0.001
Android (kg) 2.1 (1.1–3.3) 1.9 (1.5–2.9) 0.098
Gynoid (kg) 2.7 (1.9–3.8) 3.3 (2.5–4.1) 0.006
A/G ratio 0.74 ± 0.18 0.59 ± 0.19 <0.001
Visceral fat area (cm2) 153 (95–228) 126 (104–169) 0.002
Subcutaneous fat area 
(cm2)
141 (74–231) 194 (150–252) <0.001
V/S ratio 1.14 ± 0.50 0.65 ± 0.32 <0.001
Liver attenuation index 1.08 ± 0.22 1.17 ± 0.29 0.303
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covariates including ALT and HDL cholesterol (multivar-
iate model 1). Further adjustment of BMI did not attenu-
ate the significant association between A/G ratio and LAI 
(Multivariate model 2).
Cardiovascular risk prediction by A/G ratio and VFA
We next investigated whether A/G ratio could have a 
similar ability to VFA in prediction of cardiovascular 
risks such as glycemic, lipid and blood pressure con-
trol (Table 3). Other than albuminuria, the correlations 
of A/G ratio with cardiovascular risk factors (HbA1c, 
TG, HDL cholesterol, SBP, uric acid, and ALT) were 
almost similar to VFA in the univariate model. Regard-
ing the association of A/G ratio and VFA with insulin 
resistance, we used the TG/HDL cholesterol ratio as a 
surrogate marker for insulin resistance. A/G ratio was 
significantly correlated with TG/HDL cholesterol ratio 
as well as VFA.
Fig. 2 Correlation between android-to-gynoid (A/G) ratio and 
visceral fata area (VFA) in patients with type 2 diabetes. Blue and 
pink circles indicate male and female patients. p values by Pearson 
product-moment correlation analysis
Fig. 3 Correlation of android-to-gynoid (A/G) ratio (a) and visceral 
fata area (VFA) (b) with liver attenuation index (LAI) in patients with 
type 2 diabetes. p values by Pearson product-moment correlation 
analysis
Table 2 Linear regression analysis to  determine the rela-
tionship between A/G ratio and LAI in patients with type 2 
diabetes
A/G android-to-gynoid, ALT alanine aminotransferase, HDL high-density 
lipoprotein, LAI liver attenuation index
Standardized β p value
Univariate
(Adjusted R2 = 0.045)
 A/G ratio −0.223 0.002
Multivariate model 1
(Adjusted R2 = 0.076)
 A/G ratio −0.2240 0.005
 ALT −0.196 0.014
 HDL cholesterol −0.131 0.096
Multivariate model 2
(Adjusted R2 = 0.096)
 A/G ratio −0.142 0.043
 ALT −0.182 0.016
 HDL cholesterol −0.151 0.044
 Body mass index −0.196 0.017
Table 3 Univariate correlation of  A/G ratio and  VFA 
with cardio-metabolic markers in patients with type 2 dia-
betes
ACR albumin-to-creatinine ratio, A/G android-to-gynoid, ALT alanine 
aminotransferase, HDL high-density lipoprotein, TG triglycerides, VFA visceral fat 
area
A/G ratio p value VFA p value
HbA1c 0.149 0.027 0.193 0.005
Triglycerides 0.236 <0.001 0.239 <0.001
HDL cholesterol −0.192 0.004 −0.152 0.026
TG/HDL cholesterol ratio 0.234 <0.001 0.211 <0.001
Age −0.127 0.054 −0.137 0.044
Systolic blood pressure 0.346 <0.001 0.231 <0.001
Uric acid 0.305 <0.001 0.316 <0.001
ALT 0.207 0.002 0.336 <0.001
Log urinary ACR 0.052 0.463 0.147 0.044
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Association of A/G ratio and muscle mass with carotid 
atherosclerosis
Among the total subjects, 105 patients underwent carotid 
ultrasonography for the assessment of atherosclerosis 
(CIMT median 0.85 mm, IQR 0.71–1.00 mm). The inter-
action between A/G ratio and SMI was observed in the 
whole cohort (p = 0.045 in the linear regression analysis). 
Thus, we investigated the association of A/G ratio with 
CIMT in patients with low SMI and those with high SMI 
(Table 4). Among patients with low SMI (N = 65), A/G 
ratio was significantly associated with CIMT in the uni-
variate model. The statistical significance between A/G 
ratio and CIMT remained unchanged after adjusting 
for age and gender. In the multivariate linear regression 
analysis, A/G ratio and eGFR were significant predictors 
for the risk of carotid atherosclerosis. By contrast, among 
patients with high SMI (N = 40), no significant associa-
tion between A/G ratio and CIMT was observed in both 
univariate and multivariate models.
Discussion
Our study demonstrates that A/G ratio, measured by 
DXA, is correlated with visceral fat accumulation meas-
ured by CT and can estimate the risks for both NAFLD 
and atherosclerosis in patients with type 2 diabetes, 
suggesting that noninvasive and readily available meas-
ure of regional body fat (android and gynoid) by DXA 
could deserve to be considered for evaluating both 
NAFLD and atherosclerosis as well as direct measure of 
body fat by CT or MRI. We also revealed that DXA has 
the advantage of being able to simultaneously determine 
the high-risk group of atherosclerosis with high visceral 
adiposity and low muscle mass, compared with CT or 
MRI. The association between NAFLD and atherosclero-
sis has recently attracted attention over the years because 
NAFLD is thought to be a hepatic manifestation of meta-
bolic syndrome [15, 16] and is associated with progres-
sion of atherosclerosis [33, 34] and incident CVD [18]. In 
addition, a recent large-scale observational study demon-
strates that NAFLD is associated with increased CIMT in 
patients with type 2 diabetes and insulin resistance [35]. 
Thus, we sought to investigate the association of regional 
body fat and non-fat mass measured by the whole body 
DXA with the risks for both NAFLD and atherosclerosis 
among patients with type 2 diabetes.
Regional body fat measured by DXA and visceral adiposity 
measured by CT
First, we found a significant correlation between 
A/G ratio and VFA in this study. Visceral adiposity is 
thought to be located in the upstream of metabolic syn-
drome and its strong association with cardio-metabolic 
risks [6, 36, 37] and incident CVD [20] has been widely 
reported. DXA can perform for the assessment of vis-
ceral fat as shown by the good correlation of android 
measured by DXA with direct measure of visceral fat 
measured by CT [38]. The finding in this study is con-
sistent with the previous study [38] in that DXA can 
be used for the assessment of visceral adiposity with 
low cost, and high safety and availability, compared 
with CT or MRI. Furthermore, in prediction of cardio-
metabolic risks, the utility of DXA has recently been 
reported [39]. Actually, the good correlations of A/G 
ratio with markers for cardio-metabolic risks such as 
blood pressure, lipid profiles in this study well support 
the performance of DXA in prediction of cardio-meta-
bolic risks.
Association between A/G ratio and insulin resistance
Visceral obesity is accompanied by increased pro-
duction of free fatty acids, which are transported 
through the portal circulation to the liver and further 
to peripheral tissues, especially to the skeletal mus-
cle, leading to insulin resistance of peripheral tissues. 
Thus, we determined the association between A/G 
ratio and TG/HDL cholesterol ratio as the surrogate 
marker for insulin resistance [40] and found a sig-
nificant correlation between A/G ratio and TG/HDL 
Table 4 Association of  A/G ratio with  carotid atheroscle-
rosis in patients with type 2 diabetes according to skeletal 
muscle mass
ACR albumin-to-creatinine ratio, A/G android-to-gynoid, ALT alanine 
aminotransferase, HDL high-density lipoprotein, VFA visceral fat area
High SMI (N = 65) Low SMI (N = 40)
SMI ≥ 7.0 in male SMI < 7.0 in male
SMI ≥ 5.4 in female SMI < 5.4 in female
Univariate model (Adjusted R2 = 0.019) (Adjusted R2 = 0.214)
Standardized β p value Standardized β p value
 A/G ratio −0.017 0.903 0.485 0.002
Age- and gender-
adjusted model
(Adjusted R2 = 0.189) (Adjusted R2 = 0.217)
Standardized β p value Standardized β p value
 A/G ratio −0.025 0.867 0.405 0.014
 Age 0.462 0.001 0.168 0.269
 Gender 0.199 0.175 0.157 0.308
Multivariate model (Adjusted R2 = 0.336) (Adjusted R2 = 0.220)
Standardized β p value Standardized β p value
 A/G ratio 0.045 0.765 0.408 0.010
 Age 0.487 <0.001 0.175 0.252
 Gender 0.026 0.859 0.150 0.342
 Systolic blood  
pressure
0.303 0.023 0.310 0.042
 Urinary ACR 0.306 0.016 NA
 HDL cholesterol −0.309 0.025 NA
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cholesterol ratio. These observations suggest that A/G 
ratio may reflect the peripheral insulin resistance in 
addition to the utility of DXA for estimating visceral 
fat accumulation.
Association between A/G ratio and NAFLD
It is important to estimate the risk for fatty liver disease 
among diabetic patients because diabetes is a strong 
predictor for progression of NAFLD (liver cirrhosis and 
hepatocellular carcinoma) [41] and hepatic fat accu-
mulation has been reported to be associated with inci-
dent CVD in patients with type 2 diabetes [18]. In this 
study, we for the first time revealed that A/G ratio is 
significantly associated with hepatic fat accumulation in 
patients with diabetes. In addition, we recently reported 
the association of VFA and BMI with hepatic fat accu-
mulation in patients with type 2 diabetes, showing that 
patients with high VFA and normal BMI were at signifi-
cantly increased risk for prevalent fatty liver disease as 
well as those with high VFA and high BMI [32]. Thus, 
we investigated whether BMI could attenuate the asso-
ciation between A/G ratio and hepatic fat accumulation 
(multivariate model 2 in Table  2) and found that A/G 
ratio remained to be significantly associated with hepatic 
fat accumulation regardless of BMI. The finding in this 
study expands the predictive ability of DXA from vis-
ceral adiposity and cardio-metabolic risks to hepatic fat 
accumulation.
Performance of DXA for prediction of the risk 
for atherosclerosis
In this study, we found an interaction between A/G ratio 
and SMI on the risk for atherosclerosis. Thus, we divided 
patients into those with high and low SMI and performed 
linear regression analyses to investigate the association 
between A/G ratio and CIMT. Finally, we revealed that 
A/G ratio is a significant determinant of atherosclero-
sis in patients with reduced skeletal muscle; whereas, its 
relationship with CIMT was not significant in patients 
with high skeletal muscle mass. A previous study dem-
onstrated that sarcopenic obesity, defined as reduced 
skeletal muscle mass and power with increased (visceral) 
obesity, is associated with CVD events [42] and arterial 
stiffness [43]. Thus, the finding in this study suggests that 
high A/G ratio with low SMI may reflect sarcopenic obe-
sity, resulting in increased risk for carotid atherosclerosis.
Clinical implications of high A/G ratio with NAFLD 
and atherosclerosis
NAFLD is more closely associated with coronary calcifi-
cation than abdominal obesity [44]. Indeed, the severity 
of NAFLD has been associated with coronary calcifica-
tion [45]. NAFLD patients with high γ-GTP levels have 
increased risk for CVD [46]. Among patients with type 
2 diabetes, cardiac structure and function have been 
reported to be altered in those with NAFLD even without 
overt CVD [47]. In addition, NAFLD is associated with 
low-grade inflammation, oxidative stress, and changes in 
gut microbiota [48, 49]. Thus, NAFLD is thought to be 
a hepatic component of metabolic syndrome and also 
share a common pathophysiology with CVD. In this 
study, patients with high A/G ratio were at increased 
risk for both NAFLD and atherosclerosis, suggesting that 
body fat distribution may be one of the candidates that 
can account for the link between NAFLD and atheroscle-
rosis. Further studies are needed to investigate whether 
changes in body fat distribution could be associated with 
the improvement of both NAFLD and atherosclerosis.
Limitations
This study has a couple of limitations that should be men-
tioned. First, the study design was cross-sectional, which 
might preclude casual correlation. Second, population 
in this study was ethnically and socially homogeneous, 
because this study was hospital-based; therefore, general-
ization of our findings might be limited. Third, we had no 
information on muscle strength such as handgrip power. 
Thus we were unable to investigate the combined effect 
of sarcopenia and visceral adiposity on atherosclerosis, 
although we revealed the significant association between 
increased visceral adiposity with reduced muscle mass 
and carotid IMT. Fourth, we used TG/HDL cholesterol 
ratio as the surrogate marker for insulin resistance. Thus, 
further studies are needed to precisely investigate the 
association between regional fat mass by DXA and insu-
lin resistance using indices such as homeostasis model 
assessment-insulin resistance (HOMA-IR). Finally, it is 
to be elucidated whether A/G ratio could be associated 
with hepatic fat accumulation and atherosclerosis in non-
diabetic populations.
In summary, our data suggest that DXA is valuable 
to simultaneously determine increased risks for both 
hepatic fat accumulation and atherosclerosis in patients 
with type 2 diabetes.
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